IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.67 Million SEK | -90.71% |
| 2022 | 61.13 Million SEK | -70.58% |
| 2021 | 207.78 Million SEK | 69160.67% |
| 2020 | 300 Thousand SEK | 1053.85% |
| 2019 | 26 Thousand SEK | 44.44% |
| 2018 | 18 Thousand SEK | -83.49% |
| 2017 | 109 Thousand SEK | -24.31% |
| 2016 | 144 Thousand SEK | -95.0% |
| 2015 | 2.88 Million SEK | 5233.33% |
| 2014 | 54 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 42.77 Million SEK | 0.0% |
| 2024 Q3 | 9.03 Million SEK | -78.89% |
| 2024 Q1 | - SEK | 100.0% |
| 2023 Q2 | 6.87 Million SEK | 0.0% |
| 2023 Q4 | -1.19 Million SEK | 0.0% |
| 2023 FY | 5.67 Million SEK | -90.71% |
| 2023 Q3 | - SEK | -100.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2022 Q3 | 16.5 Million SEK | -29.5% |
| 2022 Q2 | 23.41 Million SEK | 158.9% |
| 2022 Q1 | 9.04 Million SEK | -25.53% |
| 2022 FY | 61.13 Million SEK | -70.58% |
| 2022 Q4 | 12.18 Million SEK | -26.19% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 207.78 Million SEK | 69160.67% |
| 2021 Q4 | 12.14 Million SEK | -93.79% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q3 | 195.64 Million SEK | 0.0% |
| 2020 Q2 | 106 Thousand SEK | -64.67% |
| 2020 Q3 | -29 Thousand SEK | -127.36% |
| 2020 Q4 | - SEK | 100.0% |
| 2020 FY | 300 Thousand SEK | 1053.85% |
| 2020 Q1 | 300 Thousand SEK | 889.47% |
| 2019 FY | 26 Thousand SEK | 44.44% |
| 2019 Q4 | -38 Thousand SEK | -72.73% |
| 2019 Q3 | -22 Thousand SEK | -184.62% |
| 2019 Q2 | 26 Thousand SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 18 Thousand SEK | -83.49% |
| 2018 Q4 | 18 Thousand SEK | 0.0% |
| 2018 Q2 | 184 Thousand SEK | 0.0% |
| 2018 Q3 | - SEK | -100.0% |
| 2017 Q1 | 43 Thousand SEK | 338.89% |
| 2017 Q2 | 5000.00 SEK | -88.37% |
| 2017 Q3 | 46 Thousand SEK | 820.0% |
| 2017 Q4 | 15 Thousand SEK | -67.39% |
| 2017 FY | 109 Thousand SEK | -24.31% |
| 2016 Q1 | 29 Thousand SEK | 0.0% |
| 2016 FY | 144 Thousand SEK | -95.0% |
| 2016 Q3 | 96 Thousand SEK | 100.0% |
| 2016 Q2 | 48 Thousand SEK | 65.52% |
| 2016 Q4 | -18 Thousand SEK | -118.75% |
| 2015 FY | 2.88 Million SEK | 5233.33% |
| 2014 FY | 54 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 90.228% |
| Ziccum AB (publ) | 3.74 Million SEK | -51.535% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.078% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 88.753% |
| Mendus AB (publ) | 28.48 Million SEK | 80.068% |
| Genovis AB (publ.) | 158.23 Million SEK | 96.412% |
| Intervacc AB (publ) | 8.01 Million SEK | 29.158% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -29.813% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 96.669% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 87.065% |
| Aptahem AB (publ) | 2.63 Million SEK | -115.84% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -448.599% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -7274.026% |
| Fluicell AB (publ) | 3.33 Million SEK | -70.102% |
| Saniona AB (publ) | 16.84 Million SEK | 66.283% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 65.393% |
| Biovica International AB (publ) | 7.29 Million SEK | 22.112% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -371.987% |
| AcouSort AB (publ) | 10.55 Million SEK | 46.185% |
| Xintela AB (publ) | 78 Thousand SEK | -7179.487% |
| Abliva AB (publ) | 137 Thousand SEK | -4044.526% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 90.142% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -181.927% |
| OncoZenge AB (publ) | 3000.00 SEK | -189166.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -3563.226% |
| CombiGene AB (publ) | 5.54 Million SEK | -2.415% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.53% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.669% |
| Corline Biomedical AB | 25.03 Million SEK | 77.315% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -687.517% |
| I-Tech AB | 120.86 Million SEK | 95.302% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 95.766% |
| Cyxone AB (publ) | 5.14 Million SEK | -10.295% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 19.461% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 46.759% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 49.439% |
| Nanologica AB (publ) | 1.44 Million SEK | -293.486% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -10613.208% |
| BioInvent International AB (publ) | 71.46 Million SEK | 92.054% |
| Alzinova AB (publ) | 270 Thousand SEK | -2002.963% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 83.878% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -288.101% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -101.205% |
| Simris Alg AB (publ) | 4.35 Million SEK | -30.409% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -4267.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 97.622% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -24586.957% |